FIIs have a tendency of going from one extreme to the other. In just 2 sessions, they have cut shorts from 2 lakh contracts to 16K contracts. Exit Polls are on Sat, Results are on Tue. Experts have recommended strategy with Risk Reward Ratio: 1:23 & max return of 28% on margin
Minda Corporation has first-mover advantage in EV products & supplies to major EV 2W firms. Buy for target price of ₹482 (13% upside): Elara Capital
With a first-mover advantage in EV products, MDA supplies to major EV 2W firms. Its smart key solution is being adopted by ICE 2W OEM, a key positive in hiking content per vehicle with realization for smart key at INR 2,500+ vs INR 400-600 for traditional locksets
PCBL has Robust volume growth & High capex intensity. Buy for target price of ₹327 (26% upside): SMIFS
PCBL reported a good show on numbers by maintaining its gross & operating spreads per kg near highest levels similar to last quarter. The good performance was backed by stronger volumes which helped maintain its operating metrics. Volumes have grown by 20% YoY & 5% QoQ because of additional volumes from Chennai (Normal carbon black) & Mundra (Speciality black) facility aiding volume momentum. We are expecting stronger pickup in volumes particularly to EU owing to ban on Russian CB supplies effective June 24 which will directly benefit Indian CB players
DERIVATIVE STRATEGIES – ELECTION 2024 by HDFC Securities
![DERIVATIVE STRATEGIES – ELECTION 2024 by HDFC Securities](https://rakesh-jhunjhunwala.in/wp-content/uploads/DERIVATIVE-STRATEGIES-–-ELECTION-2024-by-HDFC-Securities.jpg)
Election results hold immense significance for Indian markets. We are not psephologists and do not claim to have any unique insights into how this cookie will crumble. Over the past four election (2004, 2009, 2014, 2019), the Nifty experienced considerable volatility, with fluctuations of 30%, 30%, 14%, and 8%, respectively in the election month period.
Archean Chemical will benefit from increased usage of Bromine in Agrochem and Pharma, forward integration into high-value business. Buy for target price of ₹865 (39% upside):Axis Securities
The company remains confident in its Bromine Derivatives project and the strategic acquisition of Oren, which is expected to contribute to the topline in FY25. Given its smaller size and large addressable market, ACIL is optimistic about achieving 60-70% utilization from the new derivative plants. The company also anticipates continued strong uptake from the Industrial Salt segment and a recovery in the SOP segment
NRB Bearing’s valuation at 18x P/E on FY26E looks extremely attractive. Buy for target price of ₹400 (24% upside): ICICI Direct
With a healthy visibility on earnings growth and focus on strengthening balance sheet, NRB’s valuation at 18x P/E on FY26E looks extremely attractive in the bearings space (as other players quoting at 40x-52x P/E on FY26E). We believe that, company’s valuation discount to its peers (though factoring in the fact that NRB’s presence in only auto space) is unjustified to some extent. Thus, we recommend Buy on NRB Bearings with at target price of ₹ 400 (i.e. 22x FY26E P/E)
DLF has strong cash flow despite higher BD, launch pipeline intensifies. Buy for target price of ₹1081: Nuvama
We are upbeat on DLFU’s growth prospects driven by strong sectoral tailwinds (record low inventory in its home market, industry-wide consolidation, and a greater preference for branded luxury inventory), an extensive launch pipeline, and expansion of its annuity portfolio. A strong Balance Sheet, with consistent cash flow, lends comfort. We upgrade our TP to INR1,081 (from INR1,021) to account for project additions and an expanded launch pipeline. Maintain ‘BUY’
Beta Drugs is one of the fastest growing scaled up companies in the Indian branded Oncology pharma market. Buy for target price of ₹1600 (32% upside): Nuvama
Beta is one of the fastest growing scaled up companies in the Indian branded Oncology pharma market. It has shown a strong growth over the years with a bright future ahead. H2FY24 faced some pressure on the EBITDA margins due to higher raw material prices and a loss in the cosmeceutical division but the management expects a recovery in the margins in FY25
Amara Raja has a capital efficient business model, healthy net cash positive B/S & inexpensive valuations. Buy for target price of ₹1200 (28% upside): ICICI Direct
Amara Raja Energy & Mobility (AREM) is a part of the duopolistic organised Indian lead acid battery market with a strong presence across Automotive (OEM & aftermarket) and Industrial battery space (UPS, Telecom, etc.)
Recent Comments